Identifying new biomarkers for chemotherapy-related heart damage.
New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
This study is testing if new blood markers can help find heart damage early in breast cancer patients receiving chemotherapy so that doctors can make changes to their treatment right away.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Cardiology Prague Research network |
| Drugs / interventions | Chemotherapy |
| Locations | 2 sites (Prague and 1 other locations) |
| Trial ID | NCT05992337 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the early detection of cardiotoxicity in breast cancer patients undergoing chemotherapy. It aims to identify new biomarkers that can signal heart damage before significant functional impairment occurs. The methodology includes blood sampling, echocardiography, cardio MRI, and continuous monitoring of ECG and blood pressure. By detecting cardiotoxic effects early, the study seeks to enable timely adjustments in chemotherapy and initiate cardiovascular therapy to mitigate damage.
Who should consider this trial
Good fit: Ideal candidates for this study are women diagnosed with breast cancer who are undergoing chemotherapy known to have cardiotoxic side effects.
Not a fit: Patients with pre-existing cardiovascular disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved heart health outcomes for breast cancer patients receiving chemotherapy.
How similar studies have performed: Other studies have shown promise in identifying biomarkers for cardiotoxicity, but this approach may offer novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Breast cancer * Chemotherapy with a known cardiotoxic side effect Exclusion Criteria: * Known cardiovascular disease
Where this trial is running
Prague and 1 other locations
- Cardiology Prague Ltd — Prague, Czechia (Recruiting)
- Oncology Center Medicon — Prague, Czechia (Recruiting)
Study contacts
- Study coordinator: Robert Petr, MD.
- Email: robert.petr81@gmail.com
- Phone: +420 233 336 334
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.